STOCKHOLM--Swedish buyout group EQT led a series B funding extension for Swiss biotech company Noema Pharma. Noema Pharma is developing a pipeline of therapeutics that address central nervous system ...
New research reveals that fetuses can mount immune responses against infections long before birth, challenging the assumption that they rely solely on maternal immunity.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS) and metabolic disorders. Relmada’s experienced and dedicated team is committed to ...